Medicinal product discount agreements, open house
Original notice title
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No contract value provided; potential revenue may be low or uncertain.
The agreement can be terminated if an exclusive discount agreement is concluded for the same active ingredient.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 3 lots
- Duration until Feb 2027
- Non-exclusive discount agreements for 32 pharmaceutical active ingredients
- Supply of pharmaceuticals to IKK classic insured persons
Show full summary
Open House procedure by IKK classic for non-exclusive discount agreements on 32 pharmaceutical active ingredients under §130a Abs.8 SGB V. Any eligible pharmaceutical company can join at any time during the period from 01.03.2025 to 28.02.2027. Rolling submission with contract start on the 1st of the following month if documents are received by the 5th. No estimated value provided.
Risks
No contract value provided; potential revenue may be low or uncertain.
The agreement can be terminated if an exclusive discount agreement is concluded for the same active ingredient.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Only pharmaceutical entrepreneurs (or consortia thereof) as defined in §4 Abs.18 AMG may participate
Administrative
- All tender documents must be signed and submitted via email to [email protected] or by post
- Required documents: signed contract, self-declarations, commercial register extract not older than 6 months at contract start
Requirements may be incomplete.
Buyer
Lots (32)
LOT-0001
Agalsidase beta; ATC-Code: A16AB04
Discount agreement for Agalsidase beta (ATC A16AB04).
Location
Duration
Category
Deadline
Award details
Agalsidase beta
ATC-Code: A16AB04
Show original TED data
Original TED description
Agalsidase beta; ATC-Code: A16AB04
LOT-0002
Axitinib; ATC-Code: L01EK01
Discount agreement for Axitinib (ATC L01EK01).
Location
Duration
Category
Deadline
Award details
Axitinib
ATC-Code: L01EK01
Show original TED data
Original TED description
Axitinib; ATC-Code: L01EK01
LOT-0003
Carglumsäure; ATC-Code: A16AA05
Discount agreement for Carglumsäure (ATC A16AA05).
Location
Duration
Category
Deadline
Award details
Carglumsäure
ATC-Code: A16AA05
Show original TED data
Original TED description
Carglumsäure; ATC-Code: A16AA05
LOT-0004
Clobetasol; Fettsalbe, Schaum, Shampoo; ATC-Code: D07AD01
Clobetasol; Fettsalbe, Schaum, Shampoo; ATC-Code: D07AD01
Location
Duration
Category
Award details
Clobetasol
Fettsalbe, Schaum, Shampoo
ATC-Code: D07AD01
LOT-0005
Darolutamid; ATC-Code: L02BB06
Darolutamid; ATC-Code: L02BB06
Location
Duration
Category
Award details
Darolutamid
ATC-Code: L02BB06
LOT-0006
Degarelix; ATC-Code: L02BX02
Degarelix; ATC-Code: L02BX02
Location
Duration
Category
Award details
Degarelix
ATC-Code: L02BX02
LOT-0007
Dexamethason, Neomycin und Polymyxin B; ATC-Code: S01CA01 (WHO), S01CA55 (ADV)
Dexamethason, Neomycin und Polymyxin B; ATC-Code: S01CA01 (WHO), S01CA55 (ADV)
Location
Duration
Category
Award details
Dexamethason, Neomycin und Polymyxin B
ATC-Code: S01CA01 (WHO), S01CA55 (ADV)
LOT-0008
Dihydrocodein; ATC-Code: N02AA08 (WHO); R05DA14 (ADV)
Dihydrocodein; ATC-Code: N02AA08 (WHO); R05DA14 (ADV)
Location
Duration
Category
Award details
Dihydrocodein
ATC-Code: N02AA08 (WHO)
R05DA14 (ADV)
LOT-0009
Eisen(II)-sulfat; Filmtabletten, Hartkapseln, Überzogene Tabletten; ATC-Code: B03AA07
Eisen(II)-sulfat; Filmtabletten, Hartkapseln, Überzogene Tabletten; ATC-Code: B03AA07
Location
Duration
Category
Award details
Eisen(II)-sulfat
Filmtabletten, Hartkapseln, Überzogene Tabletten
ATC-Code: B03AA07
LOT-0010
Eletriptan; ATC-Code: N02CC06
Eletriptan; ATC-Code: N02CC06
Location
Duration
Category
Award details
Eletriptan
ATC-Code: N02CC06
LOT-0011
Enalapril; ATC-Code: C09AA02
Enalapril; ATC-Code: C09AA02
Location
Duration
Category
Award details
Enalapril
ATC-Code: C09AA02
LOT-0012
Esomeprazol und Naproxen; ATC-Code: M01AE52
Esomeprazol und Naproxen; ATC-Code: M01AE52
Location
Duration
Category
Award details
Esomeprazol und Naproxen
ATC-Code: M01AE52
LOT-0013
Everolimus, zur Anwendung als Immunsuppressivum nach Transplantation von Herz, Niere oder Leber; ATC-Code: L04AH02
Everolimus, zur Anwendung als Immunsuppressivum nach Transplantation von Herz, Niere oder Leber; ATC-Code: L04AH02
Location
Duration
Category
Award details
Everolimus, zur Anwendung als Immunsuppressivum nach Transplantation von Herz, Niere oder Leber
ATC-Code: L04AH02
LOT-0014
Fondaparinux; ATC-Code: B01AX05
Fondaparinux; ATC-Code: B01AX05
Location
Duration
Category
Award details
Fondaparinux
ATC-Code: B01AX05
LOT-0015
Formoterol und Glycopyrroniumbromid; ATC-Code: R03AL07
Formoterol und Glycopyrroniumbromid; ATC-Code: R03AL07
Location
Duration
Category
Award details
Formoterol und Glycopyrroniumbromid
ATC-Code: R03AL07
LOT-0016
Gentamicin; ATC-Code: J01GB03
Gentamicin; ATC-Code: J01GB03
Location
Duration
Category
Award details
Gentamicin
ATC-Code: J01GB03
LOT-0017
Gentamicin; ATC-Code: D06AX07
Gentamicin; ATC-Code: D06AX07
Location
Duration
Category
Award details
Gentamicin
ATC-Code: D06AX07
LOT-0018
Gentamicin; ATC-Code: S01AA11
Gentamicin; ATC-Code: S01AA11
Location
Duration
Category
Award details
Gentamicin
ATC-Code: S01AA11
LOT-0019
Granisetron; Injektionslösung; ATC-Code: A04AA02
Granisetron; Injektionslösung; ATC-Code: A04AA02
Location
Duration
Category
Award details
Granisetron
Injektionslösung
ATC-Code: A04AA02
LOT-0020
Isavuconazonium sulfate; ATC-Code: J02AC05
Isavuconazonium sulfate; ATC-Code: J02AC05
Location
Duration
Category
Award details
Isavuconazonium sulfate
ATC-Code: J02AC05
LOT-0021
Maraviroc; ATC-Code: J05AX09
Maraviroc; ATC-Code: J05AX09
Location
Duration
Category
Award details
Maraviroc
ATC-Code: J05AX09
LOT-0022
Menotropin; ATC-Code: G03GA02
Menotropin; ATC-Code: G03GA02
Location
Duration
Category
Award details
Menotropin
ATC-Code: G03GA02
LOT-0023
Molsidomin; Tabletten, Retardtabletten; ATC-Code: C01DX12
Molsidomin; Tabletten, Retardtabletten; ATC-Code: C01DX12
Location
Duration
Category
Award details
Molsidomin
Tabletten, Retardtabletten
ATC-Code: C01DX12
LOT-0024
Netupitant und Palonosetron; ATC-Code: A04AA55
Netupitant und Palonosetron; ATC-Code: A04AA55
Location
Duration
Category
Award details
Netupitant und Palonosetron
ATC-Code: A04AA55
LOT-0025
Ozanimod; ATC-Code: L04AE02
Ozanimod; ATC-Code: L04AE02
Location
Duration
Category
Award details
Ozanimod
ATC-Code: L04AE02
LOT-0026
Pertuzumab und Trastuzumab; ATC-Code: L01FY01
Pertuzumab und Trastuzumab; ATC-Code: L01FY01
Location
Duration
Category
Award details
Pertuzumab und Trastuzumab
ATC-Code: L01FY01
LOT-0027
Podophyllotoxin; ATC-Code: D06BB04
Podophyllotoxin; ATC-Code: D06BB04
Location
Duration
Category
Award details
Podophyllotoxin
ATC-Code: D06BB04
LOT-0028
Roxithromycin; ATC-Code: J01FA06
Roxithromycin; ATC-Code: J01FA06
Location
Duration
Category
Award details
Roxithromycin
ATC-Code: J01FA06
LOT-0029
Testosteron; 250 mg; Injektionslösung; ATC-Code: G03BA03
Testosteron; 250 mg; Injektionslösung; ATC-Code: G03BA03
Location
Duration
Category
Award details
Testosteron
250 mg
Injektionslösung
ATC-Code: G03BA03
LOT-0030
Tocilizumab; ATC-Code: L04AC07
Tocilizumab; ATC-Code: L04AC07
Location
Duration
Category
Award details
Tocilizumab
ATC-Code: L04AC07
LOT-0031
Vancomycin; ATC-Code: J01XA01
Vancomycin; ATC-Code: J01XA01
Location
Duration
Category
Award details
Vancomycin
ATC-Code: J01XA01
LOT-0032
Nilotinib; ausgenommen orale Verabreichung dispergiert in Apfelmus; ATC-Code: L01EA03
Nilotinib; ausgenommen orale Verabreichung dispergiert in Apfelmus; ATC-Code: L01EA03
Location
Duration
Category
Award details
Nilotinib
ausgenommen orale Verabreichung dispergiert in Apfelmus
ATC-Code: L01EA03
Procurement Details
- Publication date
- 20 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 547905-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No contract value provided; potential revenue may be low or uncertain.
The agreement can be terminated if an exclusive discount agreement is concluded for the same active ingredient.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications